[ Visit Client Website ]

Before you can access ASH's online program, you must agree to the following:
  • Abstracts submitted to the ASH Annual Meeting are considered embargoed from the time of submission.
  • The media, companies and institutions issuing press releases, and others are required to abide by the embargo policies governing the Society’s annual meeting. Read ASH’s embargo policy for more information.
Last updated December 3, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

622A.O1.6 Non-Hodgkin's Lymphoma - Biology, excluding Therapy: Diffuse Large B-cell lymphoma: Biology and Prognosis

Oral and Poster Abstracts
Oral Session
Monday, December 7, 2009: 2:45 PM-4:15 PM
E-1 (Ernest N. Morial Convention Center)
Moderators:
Francisco Vega and Anne J Novak, PhD
2:45 PM
ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures

Rita Shaknovich, MD/PhD1*, Huimin Geng, Ph.D.2*, Nathalie Johnson, MD3*, Leandro Cerchietti, MD2*, Maria E Figueroa, MD2, Lucas Tsikitas2*, Olivier Elemento, Ph.D.4*, Joseph M. Connors, MD5, Laurie Sehn, MD, MPH6*, Randy D. Gascoyne, MD7 and Ari Melnick, MD2

1Departments of Medicine and Pathology, Weill Cornell Medical College, New York, NY
2Hematology and Oncology Division, Weill Cornell Medical College, New York, NY
3Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, BC, Canada
4Institute for Computational Biomedicine, Weill Cornell Medical College, New York, NY
5Department of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, BC, Canada
6British Columbia Cancer Agency, Vancouver, BC, Canada
7Pathology, British Columbia Cancer Agency, Vancouver, Canada

3:00 PM
Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue:  A Study From the Lymphoma and Leukemia Molecular Profiling Project

Lisa M. Rimsza, MD1, George Wright, Ph.D.2*, Mark Schwartz, PhD3*, Wing C. Chan4, Elaine S Jaffe, MD5, Randy D. Gascoyne, MD6, Elias Campo, MD, PhD7*, Andreas Rosenwald, MD8*, German Ott, MD9*, James R. Cook, MD, PhD10, Raymond R. Tubbs, DO10, Rita M. Braziel, MD11, Jan Delabie, MD12*, Thomas P. Miller, MD13, Richard I Fisher, MD14* and Louis M. Staudt, MD, PhD2

1Pathology, University of Arizona, Tucson, AZ
2Metabolism Branch, Center for Cancer Research, National Cancer Institute, National Health Institutes, Bethesda, MD
3Research and Development, High Throughput Genomics, Tucson, AZ
4Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE
5Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD
6Pathology, British Columbia Cancer Agency, Vancouver, Canada
7Pathology, Hospital Clínic, Barcelona, Spain
8University of Wuerzburg, Wuerzburg, Germany
9Institut für Klinische Pathologie, Robert-Bosch-Krankenhaus, Stuttgart, Germany
10Clincial Pathology, Cleveland Clinic Foundation, Cleveland, OH
11Clincial Pathology, Oregon Health & Science University, Portland, OR
12Pathology, Norwegian Radium Hospital, Oslo, Norway
13Arizona Cancer Center, Tucson, AZ
14James P. Wilmot Cancer Center, Rochester, NY

3:15 PM
Molecular Profiling Identifies Plasmablasts as the Cells of Origin of Activated Diffuse Large B Cell Lymphoma

Cassandra L. Jacobs, MS1*, Patricia L. Lugar2*, Qingquan Liu3*, Jenny Zhang2*, Peter Lipsky, MD4* and Sandeep Dave, MD2

1Igsp, Duke University, Durham, NC
2Duke University, Durham, NC
3Department of Biology, the University of Toledo, Toledo, OH
4National Institutes of Health, Bethesda, MD

3:30 PM
Prediction of Survival in Diffuse Large B-Cell Lymphoma Based On the Expression of Two Genes: Integration of Tumor and Microenvironment Contributions

Ash A Alizadeh, MD, PhD1, Andrew J Gentles, PhD2*, Alvaro J. Alencar, MD3, Holbrook E Kohrt, MD1, Roch Houot, MD4*, Neha Talreja5*, Ragini Shyam5*, Yasodha Natkunam, MD, PhD6*, Randy D. Gascoyne, MD7, Javier Briones, MD8*, Ranjana Advani, MD5, Izidore S Lossos, MD9 and Ronald Levy, MD10

1Department of Medicine, Division of Hematology, Stanford University, Stanford, CA
2Radiology, Stanford University, Stanford, CA
3Medicine - Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
4Division of Oncology, Stanford School of Medicine, Stanford, CA
5Stanford University, Stanford, CA
6Stanford Univ. School of Med., Stanford, CA
7Pathology, British Columbia Cancer Agency, Vancouver, Canada
8Hospital de Sant Pau, Hematology Department, Autonomous University of Barcelona, Barcelona, Spain
9Medicine, Division of Hematology-Oncology, University of Miami Miller School of Medicine, Miami, FL, Miami, FL
10Medicine, Division of Oncology, Stanford University, Stanford, CA

3:45 PM
Classification of Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) According to the Han’s Criteria Defines Two Groups of Patients with Different Clinical Outcomes Following Systemic Rituximab-Multi Agent Anthracycline-Based Therapy

Julio Chavez, MD1*, Mark Walsh, Pharm, D2*, Francisco J Hernandez-Ilizaliturri, MD3, Anjana Elefante, Pharm, D2* and Myron S. Czuczman, MD3

1Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY
2Pharmacy, Roswell Park Cancer Institute, Buffalo, NY
3Medical Oncology and Immunology, Roswell Park Cancer Institute, Buffalo, NY

4:00 PM
MicroRNA Are Useful Biomarkers for Prediction of Response to Therapy and Survival of Patients with Diffuse Large B-Cell Lymphoma

Alvaro J. Alencar, MD1, Raquel Malumbres, PhD.2*, Ranjana Advani, MD3, Neha Talreja3*, Ragini Shyam3*, Javier Briones4*, Yaso Natkunam5*, Randy D. Gascoyne, MD6, Robert Tibshirani, PhD.7* and Izidore S. Lossos, MD, PhD2

1Department of Medicine, Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Carlsbad, NM
2Department of Medicine, Division of Hematology/Oncology, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL
3Stanford University, Stanford, CA
4Hospital de Sant Pau, Hematology Department, Autonomous University of Barcelona, Barcelona, Spain
5Stanford Univ. School of Med., Stanford, CA
6Pathology, British Columbia Cancer Agency, Vancouver, Canada
7Department of Health Research and Policy, and Statistics, Stanford University, Stanford, CA

*signifies non-member of ASH